RMG Wealth Management LLC Acquires New Holdings in Thermo Fisher Scientific Inc. $TMO

RMG Wealth Management LLC bought a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 314 shares of the medical research company’s stock, valued at approximately $131,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Hardy Reed LLC boosted its holdings in shares of Thermo Fisher Scientific by 96.9% in the second quarter. Hardy Reed LLC now owns 5,060 shares of the medical research company’s stock valued at $2,052,000 after acquiring an additional 2,490 shares in the last quarter. Roberts Wealth Advisors LLC lifted its position in Thermo Fisher Scientific by 3.9% in the second quarter. Roberts Wealth Advisors LLC now owns 8,625 shares of the medical research company’s stock worth $3,497,000 after purchasing an additional 321 shares during the period. KPP Advisory Services LLC boosted its stake in Thermo Fisher Scientific by 10.4% during the 2nd quarter. KPP Advisory Services LLC now owns 4,159 shares of the medical research company’s stock valued at $1,686,000 after purchasing an additional 391 shares in the last quarter. Wormser Freres Gestion raised its stake in shares of Thermo Fisher Scientific by 35.7% in the 2nd quarter. Wormser Freres Gestion now owns 20,793 shares of the medical research company’s stock worth $8,428,000 after buying an additional 5,475 shares in the last quarter. Finally, Valley National Advisers Inc. lifted its holdings in shares of Thermo Fisher Scientific by 1.5% in the second quarter. Valley National Advisers Inc. now owns 3,282 shares of the medical research company’s stock valued at $1,329,000 after buying an additional 50 shares during the period. 89.23% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. Scotiabank upgraded shares of Thermo Fisher Scientific from a “sector perform” rating to a “sector outperform” rating and set a $590.00 price target on the stock in a research report on Friday, July 11th. Wall Street Zen raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Saturday. Raymond James Financial reissued an “outperform” rating and set a $535.00 target price (up from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Weiss Ratings restated a “hold (c-)” rating on shares of Thermo Fisher Scientific in a research report on Saturday, September 27th. Finally, Evercore ISI reduced their price objective on Thermo Fisher Scientific from $500.00 to $480.00 and set an “outperform” rating for the company in a research note on Tuesday, July 8th. Fifteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $585.37.

Insider Activity

In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $500.96, for a total value of $5,009,600.00. Following the completion of the sale, the chief executive officer directly owned 115,174 shares of the company’s stock, valued at $57,697,567.04. This represents a 7.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Gianluca Pettiti sold 400 shares of the business’s stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the transaction, the executive vice president directly owned 22,367 shares in the company, valued at $10,735,712.66. The trade was a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 30,066 shares of company stock worth $14,182,963 in the last 90 days. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Up 0.2%

Shares of NYSE:TMO opened at $544.44 on Tuesday. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $610.97. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The company has a market cap of $205.59 billion, a PE ratio of 31.49, a price-to-earnings-growth ratio of 2.95 and a beta of 0.77. The firm has a 50 day simple moving average of $483.77 and a 200 day simple moving average of $446.95.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.22 by $0.14. The company had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company’s revenue was up 2.9% on a year-over-year basis. During the same period in the previous year, the business earned $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be given a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.95%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.